Ausgabe Sonderheft 4/2010
Controversies in Breast Cancer 2010
Inhalt (23 Artikel)
Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry
Britta Weigelt, Jorge S Reis-Filho
Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics
Christine Shiang, Lajos Pusztai
Emerging breast cancer epidemic: evidence from Africa
Sally N Akarolo-Anthony, Temidayo O Ogundiran, Clement A Adebamowo
The emerging breast cancer epidemic: early diagnosis and treatment
Anthony Howell
Introduction to session on undue and disproportionate influences
James N Ingle, William R Miller
Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?
Joseph Ragaz
Designing adjuvant treatment based on biological measurements in the neoadjuvant setting
Ian E Smith, Aekaterini Kotsori
Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
Kathleen I Pritchard
Angiogenesis - still a worthwhile target for breast cancer therapy?
Simon Lord, Adrian L Harris
Introduction: are current drug development programmes realising the full potential of new agents?
Stephen RD Johnston, Ajay Bhatanager
Are current development programs realising the full potential of new agents?
Per Eystein Lønning